BioLineRx Ltd.
BLRXNASDAQHealthcare● Active
$3.12
$-0.11(-3.32%)
Market Cap$13588853
P/E Ratio—
52W High$6.59
52W Low$2.15
BioLineRx Ltd. (BLRX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · BLRX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.19M | $28.94M | $4.80M | $0.00M | $0.00M |
| Cost of Revenue | $0.76M | $9.26M | $3.69M | $0.00M | $0.00M |
| Gross Profit | $0.43M | $19.68M | $1.11M | $0.00M | $0.00M |
| Gross Margin %(computed) | 36.19% | 67.99% | 23.08% | — | — |
| Operating Expenses | |||||
| R&D Expenses | $7.66M | $9.15M | $12.52M | $17.63M | $19.47M |
| G&A Expenses | $0.00M | $18.46M | $16.64M | $5.07M | $4.27M |
| Total Operating Expenses | $10.80M | $40.09M | $50.80M | $29.16M | $24.78M |
| Operating Income | ($10.37M) | ($20.41M) | ($49.69M) | ($29.16M) | ($24.78M) |
| Operating Margin %(computed) | -871.78% | -70.52% | — | — | — |
| Interest Income | $1.13M | $1.83M | $2.01M | $0.69M | $0.56M |
| Interest Expense | $1.29M | $9.16M | $2.17M | $2.16M | $0.98M |
| Income Before Tax | ($2.04M) | ($9.22M) | ($60.61M) | ($24.95M) | ($27.05M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($1.18M) | ($9.22M) | ($60.61M) | ($24.95M) | ($27.05M) |
| Net Margin %(computed) | -99.58% | -31.86% | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.29 | $-0.12 | $-0.94 | $-0.48 | $-0.61 |
| Wtd Avg Shares | 4.11M | 79.87M | 64.22M | 51.60M | 44.20M |
| EBITDA | ($9.84M) | $3.92M | ($57.09M) | ($28.50M) | ($24.07M) |
| EBITDA Margin %(computed) | -827.46% | 13.54% | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more BioLineRx Ltd. data
About BioLineRx Ltd. (BLRX) Income Statement
BioLineRx Ltd. (BLRX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, BLRX reported revenue of $0.00B, gross profit of $0.00B (gross margin 36.19%), and net income of ($0.00B) — a net profit margin of -99.58%.
Frequently asked questions
BLRX · 4 questionsBioLineRx Ltd. (BLRX) reported revenue of $0.00B for 2025, down 95.9% year-over-year.
BLRX revenueBLRX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08